

1 **Amplification of human  $\beta$ -glucoronidase gene for appraising the accuracy of**  
2 **negative SARS-CoV-2 RT-PCR results in upper respiratory tract specimens**

3 Eliseo Albert<sup>1</sup>, Blanca Ferrer<sup>2</sup>, Ignacio Torres<sup>1</sup>, Alicia Serrano<sup>2</sup>, María Jesús Alcaraz<sup>1</sup>,  
4 Javier Buesa<sup>1,3</sup>, Carlos Solano<sup>2,4</sup>, Javier Colomina<sup>1</sup>, Felipe Bueno<sup>1</sup>, Dixie Huntley<sup>1</sup>,  
5 Beatriz Olea<sup>1</sup>, Arantxa Valdivia<sup>1</sup>, David Navarro<sup>1,3</sup>

6 <sup>1</sup>*Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute,*  
7 *Valencia, Spain.*

8 <sup>2</sup>*Hematology Service, Hospital Clínico Universitario, INCLIVA Research Institute,*  
9 *Valencia, Spain.*

10 <sup>3</sup>*Department of Microbiology, School of Medicine, University of Valencia, Valencia,*  
11 *Spain.*

12 <sup>4</sup>*Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.*

13

14 **Correspondence:** David Navarro, Microbiology Service, Hospital Clínico  
15 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of  
16 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010  
17 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; Email:  
18 david.navarro@uv.es.

19

20

21

22

23

24 ABSTRACT

25 Real-time reverse transcription polymerase-chain reaction (RT-PCR) is the mainstay of  
26 Covid-19 diagnosis. False-negative RT-PCR results may hamper clinical management  
27 of patients and hinder the adoption of epidemiological measures to control the  
28 pandemic. The current study was aimed at assessing whether amplification of  $\beta$ -  
29 glucuronidase (GUSB) gene would help estimate the accuracy of SARS-CoV-2 RT-  
30 PCR negative results in upper respiratory tract (URT) specimens. URT specimens that  
31 tested negative by SARS-CoV-2 RT-PCR displayed higher GUSB RT-PCR cycle  
32 thresholds (CT) (P=0.070) than those testing positive (median, 30.7; range, 27.0-40.0,  
33 and median 29.7; range 25.5-36.8, respectively), this reflecting poorer cellularity.  
34 Receiver operating characteristic (roc) curve analysis indicated that a CT threshold of  
35 31.2 discriminated best between positive and negative SARS CoV-2 RT-PCRs (area  
36 under a curve, 0.66; 95% CI, 0.50-0.81; P=0.08). This cut-off yielded a true negative  
37 ratio of 89% and accuracy of 70%. The data suggested that amplification of the GUSB  
38 gene by RT-PCR may help to appraise the accuracy of negative SARS-CoV-2 RT-PCR  
39 results in patients in whom Covid-19 is eventually diagnosed.

40

41

42

43

44

45

46 Real-time reverse transcription polymerase-chain reaction (RT-PCR) is the mainstay of  
47 Covid-19 diagnosis.<sup>1</sup> Up to 30% of patients clinically suspected of Covid-19 may have  
48 initial or repeat RT-PCR negative results prior to positive test conversion, most notably  
49 when upper respiratory tract (URT) specimens are processed.<sup>2-7</sup> False-negative RT-PCR  
50 results may hamper clinical management of patients and hinder the adoption of  
51 epidemiological measures to control the pandemic. A number of pre-analytical and  
52 analytical factors may impact on the diagnostic efficiency of RT-PCR, including the  
53 type of and time to specimen processing, conservation prior to testing, quality of  
54 samples, timing of sample collection after symptoms onset or the intrinsic performance  
55 of the assay (i.e. limit of detection-LOD-).<sup>2,8</sup> A large number of commercially-available  
56 SARS-CoV-2 RT-PCR assays targeting one or more SARS-CoV-2 genes have been  
57 launched and have reached global widespread use.<sup>9</sup> Most of these assays include a  
58 spike-in control for RT-PCR amplification, such as MS2 phage RNA genome, but  
59 provide no information on specimen cellularity, since no primers targeting human  
60 housekeeping genes (i.e. RNase P) are included in the reaction. The current study was  
61 aimed at assessing whether amplification of  $\beta$ -glucuronidase (GUSB) gene would help  
62 estimate the accuracy of SARS-CoV-2 RT-PCR negative results in URT samples.

63 As shown in Figure 1, 202 patients eventually diagnosed with Covid-19, either by RT-  
64 PCR (n=191) or serological methods (n=11), were admitted to our center (median age,  
65 65 years; range, 3-98 years; 115 male and 87 female) until April 14. A total of 199  
66 patients received a final diagnosis of Covid-19 on clinical, laboratory and imaging  
67 grounds, without microbiological documentation. The study was approved by the local  
68 Ethics Committee (INCLIVA).

69

70 Of the 202 patients, 34 (16.8%) tested negative by RT-PCR on first URT specimens,  
71 collected at a median of 5 days (range, 1-14 days) after the onset of symptoms. In these  
72 patients, as per protocol, URT swabs were collected every 24-72 h until RT-PCR  
73 positive conversion. Twenty-three patients tested positive by RT-PCR in the second  
74 (n=18) or third (n=5) URT sample. Diagnosis of Covid-19 was achieved by serological  
75 methods in the remaining 11 patients. Sera from these patients were drawn at a median  
76 of 12 days (range, 10-21 days) after admission. The presence of either SARS-CoV-2  
77 IgM (determined by the MAGLUMI 2019-nCoV SARS-CoV-2- IgM assay on the fully  
78 automated MAGLUMI analyzers-SNIBE – Shenzhen New Industries Biomedical  
79 Engineering Co., Ltd, Shenzhen, China), IgG (Euroimmun anti-SARS-CoV-2 IgG  
80 assay; Euroimmun, Luebeck, Germany), or both confirmed diagnosis of Covid-19.

81 A total of 47 URT specimens (26 and 21 specimens yielding negative or positive  
82 SARS-CoV-2 RT-PCR results, respectively) from 21 of the above-mentioned 23  
83 patients were subjected to GUSB gene RT-PCR analysis, which was performed in a  
84 parallel to viral RT-PCR testing. To this end, we used the HEQC-one step kit  
85 (Seqplexing, Valencia, Spain), a one-Step real-time RT-PCR. RNA was extracted from  
86 clinical samples using the DSP virus Pathogen Minikit on the QiaSymphony Robot  
87 instruments (Qiagen, Valencia, CA, USA), reverse transcribed to cDNA and  
88 subsequently amplified in the LightCycler 480 Real-Time PCR System Version II  
89 (Roche Diagnostics, Pleasanton, USA). Cy5 fluorescent signal (618-660 nm) revealed  
90 amplification of the target gene.

91 URT specimens that tested negative by SARS-CoV-2 RT-PCR displayed higher GUSB  
92 RT-PCR cycle thresholds (CT) ( $P=0.070$ ; Mann-Whitney U test) than those testing  
93 positive (median, 30.7; range, 27.0-40.0, and median 29.7; range 25.5-36.8,  
94 respectively), this reflecting poorer cellularity. Receiver operating characteristic (roc)

95 curve analysis (not shown) indicated that a  $C_T$  threshold of 31.2 discriminated best  
96 between positive and negative SARS CoV-2 RT-PCRs (area under a curve, 0.66; 95%  
97 CI, 0.50-0.81;  $P=0.08$ ). This cut-off yielded a true negative ratio of 89% and accuracy  
98 of 70% (Table 1).

99 The current study has several limitations that should be acknowledged. First, a  
100 relatively scarce number of specimens were subjected to GUSB gene analysis. Second,  
101 consecutive specimens from a given patient could have been tested by different SARS-  
102 CoV-2 RT-PCR assays displaying distinct LOD. Third, regardless of the specimen  
103 cellularity, SARS CoV-2 load may have been intrinsically lower in patients testing  
104 negative than in those testing positive, although this possibility seems unlikely given the  
105 dynamics of viral load in URT specimens during the course of Covid-19, which peaks  
106 within the first week after onset of symptoms.<sup>10,11</sup> In this sense, as stated, first and  
107 second SARS-CoV-2 RT-PCR negative specimens were usually collected within this  
108 time frame. In summary, our data suggested that amplification of the GUSB gene by  
109 RT-PCR may help to appraise the accuracy of negative SARS-CoV-2 RT-PCR results  
110 in patients in whom Covid-19 is eventually diagnosed. Further studies are warranted to  
111 validate this assumption.

## 112 **ACKNOWLEDGMENTS**

113 No public or private funds were used for the current study. We are grateful to all  
114 personnel working at Microbiology Service of Clinic University Hospital for their  
115 unwavering commitment in the fight against Covid-19. We are indebted to all  
116 colleagues who attended the patients, in particular to Josep Redón, María Luisa Blasco,  
117 Jaime Signes-Costa, María José Galindo, and María José Forner.

## 118 **CONFLICT OF INTERESTS**

119 The authors declare no conflicts of interests.

## 120 **AUTHOR CONTRIBUTIONS**

121 EA, BF, IT, AS, and CS performed the GUSB gene RT-PCR analyses and designed the  
122 study. MJA performed the serological tests. JB, JC, FB, DH, BO, AV performed SARS-  
123 CoV-2 RT-PCR tests. DN designed the study, analyzed the data and wrote the  
124 manuscript. All authors reviewed and approved the final version of the manuscript.

## 125 **REFERENCES**

- 126 1. Laboratory testing strategy recommendations for COVID-19: interim guidance.  
127 WHO/2019-nCoV/lab\_testing/2020.1
- 128 2. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative  
129 results of initial RT-PCR assays for Covid-19: a systematic review. *MedRxiv preprint*  
130 2020; doi: <https://doi.org/10.1101/2020.04.16.20066787>.
- 131 3. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing 448 in  
132 Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology*.  
133 2020:200642.
- 134 4. Bernheim A, Mei X, Huang M, et al. Chest CT Findings in 451 Coronavirus Disease-  
135 19 (COVID-19): Relationship to Duration of Infection. *Radiology*. 2020:200463.
- 136 5. Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to  
137 RT-PCR. *Radiology*. 2020:200432.
- 138 6. Li Y, Yao L, Li J, Chen L, Song Y, Cai Z, Yang C. Stability issues of RT-PCR  
139 testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. *J*  
140 *Med Virol*. 2020; Mar 26. doi: 10.1002/jmv.25786.

141 7. Winichakoon P, Chaiwarith R, Liwsrisakun C, et al. Negative Nasopharyngeal and  
142 Oropharyngeal Swabs Do Not Rule Out COVID-19. *J Clin Microbiol.* 2020;58(5). pii:  
143 e00297-20.

144 8. Lowe CF, Matic N, Ritchie G, et al. Detection of low levels of SARS-CoV-2 RNA  
145 from nasopharyngeal swabs using three commercial molecular assays. *J Clin Virol.*  
146 2020 Apr 28;128:104387.

147 9. FIND EVALUATION UPDATE: SARS-COV-2 MOLECULAR DIAGNOSTICS.  
148 <https://www.finddx.org/covid-19/sarscov2-eval-molecular/>.

149 10. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-  
150 19. *Lancet Infect Dis.* 2020; pii: S1473-3099(20)30232-2.

151 11. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory  
152 Specimens of Infected Patients. *N Engl J Med.* 2020; 382:1177-1179.


153

154 **FIGURE 1.** SARS-CoV-2 RT-PCR and serology testing results in patients with clinical  
155 suspicion of Covid-19 admitted to Hospital Clínico Universitario of Valencia during the  
156 study period. Nasopharyngeal or Oropharyngeal swabs were obtained with flocked  
157 swabs in universal transport medium (Beckton Dickinson, Sparks, MD, USA, or Copan  
158 Diagnostics, Murrieta, CA, USA) and conserved at 4 ° C until processed (within 6  
159 hours). Nucleic acid extraction was performed using the Qiagen EZ-1 Viral extraction  
160 kit or the DSP virus Pathogen Minikit on the EZ1 or QiaSymphony Robot instruments  
161 (Qiagen, Valencia, CA, USA), respectively. Commercially-available PCR assays used  
162 for SARS CoV-19 testing included the LightMix® Modular SARS-CoV-2 (COVID-19)  
163 E-gene/LightMix® Modular SARS-CoV-2 (COVID-19) RdRP gene from TIB  
164 MOLBIOL GmHD, distributed by Roche Diagnostics (Pleasanton, CA, USA) on the

165 Light Cycler 2.0 instrument, the SARS-COV-2 REALTIME PCR KIT from Vircell  
166 Diagnostics (Granada, Spain), or the REALQUALITY RQ-2019-nCoV from AB  
167 ANALITICA (Padua, Italy), both on the Applied Biosystems 7500 instrument and the  
168 SARS-CoV-2 (S gene) – BD MAX™ System (VIASURE Real Time PCR Detection  
169 Kits; CerTest, Zaragoza, Spain). Results were interpreted according to the respective  
170 manufacturer's instructions.

171





**TABLE 1. Accuracy of negative SARS-CoV-2 RT-PCR results in upper respiratory tract specimens from patients with microbiological diagnosis of Covid-19 upon  $\beta$ -glucoronidase gene RT-PCR  $C_T$  value**

| $\beta$ -glucoronidase gene $C_T$ | SARS-CoV-2 RT-PCR     |                       |
|-----------------------------------|-----------------------|-----------------------|
|                                   | Positive <sup>a</sup> | Negative <sup>b</sup> |
| $\leq 31.2$                       | 18                    | 18                    |
| $> 31.2$                          | 3                     | 8                     |

$C_T$ , RT-PCR cycle threshold.

<sup>a</sup>The REALQUALITY RQ-2019-nCoV was used in 7 specimens. The LightMix® Modular SARS-CoV-2 (COVID-19) E-gene/LightMix® Modular SARS-CoV-2 (COVID-19) RdRP gene was used in 6 specimens. The SARS-COV-2 REALTIME PCR KIT was used in 4 specimens. The SARS-CoV-2 (S gene) – BD MAX™ System (VIASURE Real Time PCR Detection Kits) was used in 4 specimens.

<sup>b</sup>The LightMix® Modular SARS-CoV-2 (COVID-19) was used in 17 specimens. The REALQUALITY RQ-2019-nCoV was used in 6 specimens. The SARS-COV-2 REALTIME PCR KIT was used in 3 specimens.